




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach

Ishtiaque Ahammad ^{a,*}, Samia Sultana Lira ^{b,1}

^a Department of Biochemistry and Microbiology, North South University, Dhaka 1229, Bangladesh

^b Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka 1000, Bangladesh



ARTICLE INFO

Article history:

Received 3 May 2020

Received in revised form 16 June 2020

Accepted 22 June 2020

Available online 26 June 2020

Keywords:

SARS-CoV-2

mRNA vaccine

Immunoinformatics

ABSTRACT

SARS-CoV-2 is the deadly virus behind COVID-19, the disease that went on to ravage the world and caused the biggest pandemic 21st century has witnessed so far. On the face of ongoing death and destruction, the urgent need for the discovery of a vaccine against the virus is paramount. This study resorted to the emerging discipline of immunoinformatics in order to design a multi-epitope mRNA vaccine against the spike glycoprotein of SARS-CoV-2. Various immunoinformatics tools were utilized to predict T and B lymphocyte epitopes. The epitopes were channeled through a filtering pipeline comprised of antigenicity, toxicity, allergenicity, and cytokine inducibility evaluation with the goal of selecting epitopes capable of generating both T and B cell-mediated immune responses. Molecular docking simulation between the epitopes and their corresponding MHC molecules was carried out. 13 epitopes, a highly immunogenic adjuvant, elements for proper sub-cellular trafficking, a secretion booster, and appropriate linkers were combined for constructing the vaccine. The vaccine was found to be antigenic, almost neutral at physiological pH, non-toxic, non-allergenic, capable of generating a robust immune response and had a decent worldwide population coverage. Based on these parameters, this design can be considered a promising choice for a vaccine against SARS-CoV-2.

© 2020 Elsevier B.V. All rights reserved.

1. Introduction

After more than a century has passed since the 1918 influenza pandemic and after two other pandemics caused by the coronavirus family

Abbreviations: ACE2, angiotensin converting enzyme 2; AI, aliphatic index; ARCA, anti-reverse cap analogs; ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease-19; CTL, cytotoxic T lymphocyte; dsRNA, double-stranded RNA; GMP, good manufacturing practice; GM-CSF, granulocyte macrophage colony-stimulating factor; GRAVY, grand average of hydropathicity; HIV, human immunodeficiency virus; HSV, herpes simplex virus; HLA, human leukocyte antigen; HPLC, high-performance liquid chromatography; HTL, helper T lymphocyte; ICTV, international committee on taxonomy of viruses; IFN- γ , interferon- γ ; Ig, immunoglobulin; IL, instability index; IL-4, interleukin 4; IL-10, interleukin 10; LBL, linear B lymphocyte; LNP, lipid nanoparticle; MERS, Middle East Respiratory Syndrome; MERS-CoV, middle east respiratory syndrome corona virus; MHC, major histocompatibility complex; MITD, MHC I-targeting domain; NMR, nuclear magnetic resonance; ORF, open reading frame; PAMP, pathogen-associated molecular pattern; pAPC, professional antigen presenting cells; pDNA, plasmid DNA; PHEIC, public health emergency of international concern; PSSM, position-specific scoring matrix; RBD, receptor-binding domain; RBM, receptor-binding motif; RTC, replication/transcription complex; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS CoV-2, severe acute respiratory syndrome coronavirus 2; TAP, transporter associated with antigen processing; TCR, T-cell receptor; TLR, toll-like receptors; TMPRSS2, transmembrane protease serine S1 member 2; tPA, tissue plasminogen activator; UTR, untranslated regions; ViPR, virus pathogen database and analysis resource; WHO, world health organization.

* Corresponding author at: Bashundhara, Dhaka 1229, Bangladesh.

E-mail address: ishtiaque.ahammad@northsouth.edu (I. Ahammad).

¹These authors have contributed equally.

called the Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) in the past two decades, the world has been visited by a novel coronavirus. As of mid-April 2020, the Coronavirus Disease (COVID-19) has reached 213 countries, areas and territories of the world infecting nearly two million people and leaving over a hundred thousand dead since the first case of hospitalization on 12th December 2019 in Wuhan, China [1,2]. The causative entity for COVID-19 was named by the International Committee on Taxonomy of Viruses (ICTV) on 11th February 2020 as “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”, previously known as 2019-novel Coronavirus (2019-nCoV) [3,4]. Coronaviruses are members of the sub-family *Coronavirinae* (family: *Coronaviridae*) which consists of four genera- *Alphacoronavirus*, *Betacoronavirus*, *Gammacoronavirus* and *Deltacoronavirus*. Among the six zoonotic viruses known prior to identification of SARS-CoV-2 in 2019, only the SARS-CoV and MERS-CoV belonging to the *Betacoronavirus* genera were considered highly pathogenic [5,6]. The virus has been reported to cause Acute Respiratory Distress Syndrome (ARDS) in humans by infecting the upper and lower respiratory tract. Even though the SARS-CoV-2 has been found to infect principally *via* the respiratory tract from human to human, evidence from multiple studies indicated the gastrointestinal tract to be another potential route of infection [7–10]. Typical symptoms of the disease include fever, cough, dyspnea, diarrhea, fatigue and vomiting [11–15]. The median incubation period of the virus and the median time from the

first symptom to death are 3 days (with a range of 0 to 24 days) and 14 days (with a range of 6 to 41 days) respectively [16,17].

Like other coronaviruses, the SARS-CoV-2 is an enveloped virus with a linear single-stranded positive-sense RNA (+ssRNA) as its genomic material [18–20]. Its 29,881 bases long genome encodes at least four major structural proteins, namely spike glycoprotein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N). The virus also possesses a probable proofreading function using a Replication/Transcription Complex (RTC) [20–26]. In coronaviruses, homotrimers of the S protein radiate from the virus surface giving the virus a characteristic crown-like appearance and these crown-like structures are what is behind their name (“corona” means crown in Latin). In case of SARS-CoV-2, the S protein mediates viral entry into host cells by binding to the host receptor, Angiotensin-converting Enzyme 2 (ACE2) through the Receptor-binding Domain (RBD) of the S1 subunit. Upon S1-ACE2 binding, the cleavage of the S1-S2 fusion peptide by the cellular protease, ‘Transmembrane Protease Serine S1 Member 2’ (TMPRSS2) takes place. This is followed by the fusion of viral and host membranes through the S2 subunit [27–32]. However, one study has proposed that the cleavage of a furin dependent furin-cleavage site in S protein takes place prior to membrane fusion [33]. TMPRSS2 expression is restricted to lung and gastrointestinal tract only, whereas ACE2 is found to be expressed in cells of other organs including liver, heart, vascular endothelium, testis, and kidney [34–36].

High degree of contagiousness and community transmission of COVID-19 leading to the World Health Organization's (WHO) declaration of a Public Health Emergency of International Concern (PHEIC) calls for immediate development of safe and effective prophylactics or therapeutics. To date, there is no approved vaccine or drug in the market for the disease although some pre-clinical and clinical trials are underway [37]. As S protein plays a crucial role in viral fusion and entry, it is widely considered as a prime target for the development of antibodies, entry inhibitors and vaccines against SARS-CoV-2 by the scientific community [38–47]. In our study, we have also decided to target this S protein for designing an mRNA vaccine.

Conventional vaccine approaches, such as live attenuated and inactivated pathogens and subunit vaccines successfully provide durable protection against infectious diseases [48,49], but the need for more rapid development and large-scale production is hard to meet through these means. Also peptide-based vaccines have been reported to have lower immunogenicity indexes [50]. Although genetic immunization such as DNA vaccines showed promise [51], plasmid DNA (pDNA) based delivery evokes safety concerns such as the possibility of insertional mutagenesis. To address these complications, the rapidly growing field of mRNA therapeutics can be a potent platform because of its safety, comparatively low-cost of production, capability of rapid development and higher efficacy. Except for a few rare cases of recombination between single-stranded RNA molecules [52,53], lack of genomic integration and replication makes mRNA vaccines a non-infectious agent [54,55]. On top of that, natural degradation and adjustable half-life provides a strong safety advantage [55]. As mRNA vaccines do not have to pass through nuclear envelope for translation, it possesses higher efficacy over DNA vaccines [55,56]. Mere alteration of an mRNA sequence can express a different protein having new indications and antigens using the already established production process, resulting in manufacturing versatility, flexibility, time-saving and cost-reduction [57,58]. Although mRNA vaccines come with inherent shortcomings such as instability, immunogenicity, delivery inefficiency [59,60], these have been addressed by recent advancements in synthesis and manipulation via structural modifications of mRNA leading to some successful outcomes [61–63].

Immunoinformatics is a branch of bioinformatics that deals with the computational analysis of immunological data. It is also a powerful computational tool for designing vaccines [64]. By predicting appropriate antigens, epitopes, carriers, and adjuvants for a vaccine, immunoinformatics is able to reduce the timeframe and cost of vaccine

development [65]. Immunoinformatics approach has been followed for designing vaccines against many infectious agents such as ebola virus, Human Immunodeficiency Virus (HIV-1), Herpes Simplex Virus (HSV)-1 & 2, sudan virus, Venezuelan equine encephalitis virus, human norovirus, *Staphylococcus aureus*, *Shigella* spp. and so on [66–73].

Some of the recently published bioinformatic studies on SARS-CoV-2 vary from our work in several ways. Two studies have selected epitopes from SARS-CoV-2 domains homologous to SARS-CoV [74,75]. One of them has identified the epitopes associated with previous experimental success in SARS-CoV neutralization. However, practically, the antibodies working against SARS-CoV (S230, m9396,80R) have been found to show no cross-reactivity except for one case (CR3022) as of 14 June 2020 [76,77]. These findings stress the importance of focusing on the sequence of SARS-CoV-2 as we did in our study. Besides, unlike these studies which took into consideration proteins other than S, we attended only to the S protein because of its promising therapeutic importance in previous cases of corona viruses [40,43,45,46]. Besides, in the aforementioned studies, only potential epitopes have been predicted, but no vaccine construct has been designed.

Two other studies also have designed vaccines for SARS-CoV-2 in an approach similar to ours mainly differing in the fact that we opted for more effective, flexible and safe approach of mRNA-vaccination rather than peptide-based vaccines [78,79]. Contextually, Lucchese et al. [80] sought out epitopes unmatched to human ones in order to minimize the risk for cross-reactions and increase anti-viral specificity. In our study, we also ensured avoiding human proteome cross-reactivity while filtering the epitopes. Robson et al. [81] found out one conserved region in coronaviruses using the programming language Q-UDEL.

In this study, we aimed at designing a novel multi-epitope mRNA vaccine consisting of Cytotoxic T Lymphocyte (CTL), Helper T Lymphocyte (HTL), Linear B Lymphocyte (LBL) epitopes derived from SARS-CoV-2 spike glycoprotein, a highly immunogenic adjuvant and other necessary elements through immunoinformatics.

2. Materials and methods

2.1. Workflow used for the study

Fig. 1 shows the workflow that has been followed in this study. The analyses conducted in this study can be broken down into 9 sections - 1. Retrieval of SARS-CoV-2 spike glycoprotein sequence 2. Prediction and assessment of CTL epitopes 3. Prediction and assessment of HTL epitopes 4. Prediction and assessment of LBL epitopes 5. Multiple Sequence Alignment of S protein sequences 6. Molecular docking between T lymphocyte epitopes and MHC alleles 7. Prediction of population coverage 8. Designing the vaccine construct 9. Prediction of antigenicity, allergenicity, toxicity and physicochemical properties of the vaccine construct 10. *In silico* immune simulation.

2.2. Retrieval of SARS-CoV-2 spike glycoprotein sequence

The Virus Pathogen Database and Analysis Resource (ViPR) was used to search the complete SARS-CoV-2 genomes [82]. From the results, the FASTA sequence of the surface glycoprotein, also known as the spike glycoprotein, from the “2019-nCoV_WHU01” strain was downloaded. This strain was isolated on 2nd January 2020 from Wuhan, China. The GenBank [83] accession number of the protein was QHO62107.1.

2.3. Prediction and assessment of CTL epitopes

CTLs also known as CD8+ T cells play a cardinal role in the battle against viral infections. The mechanism of CTL response against viruses has been elucidated in great detail by various studies [84–87]. Class I MHC-bound epitopes generated from degraded fragments of viral proteins are recognized on the surface of infected cells by CTLs [88].




Fig. 1. Workflow used for designing the mRNA vaccine against SARS-CoV-2. The whole process can be divided into two parts, pre-vaccine construction and post-vaccine construction analyses. Pre-vaccine construction analyses include the retrieval of spike glycoprotein sequence, prediction of T and B cell epitopes, population coverage prediction and molecular docking between the T cell epitopes and their MHC alleles. Post-vaccine construction analyses include the antigenicity, allergenicity, toxicity and physiochemical assessments of the vaccine construct and the simulation of immune response against the vaccine.

Prediction of potential CTL epitopes is an essential and widely used step in *in silico* vaccine design [89–91]. There are various immunoinformatics tools that are used for CTL epitope prediction. In this study, NetCTL v1.2 server was used for the prediction of 9-mer CTL epitopes for 12 MHC class I supertypes, namely A1, A2, A3, A24, A26, B7, B8, B27, B39, B44, B58, and B62. 0.75 was used as the threshold for epitope identification. For any given protein, NetCTL v1.2 integrates information about proteasomal cleavage, Transporter Associated with Antigen Processing (TAP) transport efficiency, and MHC class I affinity to deliver its final output [92]. Class I immunogenicity tool of the IEDB Analysis Resource [93] was used to predict the immunogenicity of the CTL epitopes. Only epitopes that showed a positive value for immunogenicity were kept for the next stage of evaluation. Toxicity and allergenicity of the immunogenic epitopes were checked using ToxinPred [94] and AllerTOP 2.0 [95] servers respectively. The non-toxic and non-allergenic epitopes were subjected to Vaxijen server [96] for antigenicity evaluation. Epitopes showing antigenicity prediction values ≥ 0.5 were considered antigenic. Using the consensus algorithm [97] in the IEDB server, MHC class I allelic partners of the antigenic epitopes were predicted. A percentile rank score ≤ 2 was considered for this study.

2.4. Prediction and assessment of HTL epitopes

After proteolytic cleavage of viral antigens, antigen presenting cells such as B cells, macrophages and dendritic cells present epitopes to HTLs or CD4+ T cells in the epitope-MHC class II complex form [98]. Almost all immunoinformatics studies for vaccine construction incorporate the prediction of HTL epitopes as part of their work [99–101]. In our study, 15-mer HTL epitopes and their corresponding MHC class II alleles were predicted using the consensus algorithm of the IEDB MHC-II binding tool [102]. Host species was selected as human. A percentile rank ≤ 0.25 was considered for filtering the epitopes. Antigenicity of the epitopes were then calculated using the Vaxijen server [96]. ToxinPred and AllerTOP 2.0 servers were used in subsequent order to select the non-toxic and non-allergenic epitopes respectively. The remaining epitopes were then checked for their inducibility of

interferon- γ (IFN- γ), interleukin-4 (IL-4) and interleukin-10 (IL-10) using the IFNepitope [103], IL4pred [104], and IL10pred [105] servers respectively. Based on these criteria, only the antigenic and all three cytokine inducing epitopes were selected for vaccine construction.

2.5. Prediction and assessment of LBL epitopes

B lymphocytes secrete specific antibodies in order to neutralize specific viral invaders. Through differentiation into long-lived plasma cells and memory B lymphocytes they ensure long term immunological protection [106–111]. Activation of B lymphocytes takes place through the binding of B cell receptor to either soluble or membrane bound epitopes [112]. In vaccine design, reliable prediction of B lymphocyte epitopes through the use of various computational tools plays an important part [113,114]. B lymphocyte epitopes can be of two types-linear and conformational [113]. In this study, iBCE-EL server was used for the prediction of LBL epitopes [115]. Only the ones positively predicted to be LBL epitopes by the server were chosen for further analysis. The antigenicity of the probable LBL epitopes was checked by the Vaxijen server [96]. Epitopes having antigenicity values ≥ 0.5 were then evaluated for toxicity and allergenicity using the ToxinPred [94] and AllerTOP 2.0 [95] servers respectively.

2.6. Multiple sequence alignment of S protein sequences

To check on whether the regions selected for epitopes have faced any mutation, 200 randomly selected S protein sequences from 6 continents (Asia, Africa, Europe, Oceania, North and South America) were downloaded from ViPR database and then aligned using Clustal Omega server [116]. The results were viewed using MView multiple alignment viewer [116].

2.7. Molecular docking between T lymphocyte epitopes and MHC alleles

Binding affinity of CTL and HTL epitopes for their corresponding MHC alleles was evaluated using molecular docking simulation. At

Table 1
List of selected epitopes for vaccine construction.

Recognizing cell	Epitope sequence
CD8+ cytotoxic T lymphocyte	RQIAPGQTG
	VVFLHVITYV
	GVVFLHVITY
	GQTGKIADY
	QLTPTWRVY
CD4+ helper T lymphocyte B lymphocyte	IAIVMVTIM
	DLPIGINITRFQTL
	GVSPTKLNLDLCF
	IAPGQTGKIADY
	QIAPGQTGKIAD
	LVDLPIGINITR
	DLPIGINITRFQ
	PLVDLPIGINIT

first, the MHC alleles were downloaded from the RCSB PDB [117,118] and processed using the PyMOL software [119] for getting rid of unnecessary ligands. The structures were then energy minimized using the Swiss-PdbViewer [118]. The epitopes were folded into their 3 dimensional form using the PEP-FOLD 3.5 server [118]. They were then also energy minimized using the Swiss-PdBViewer. The docking between the epitopes and the MHC molecules were carried using Autodock Vina [120] in PyRx [121]. PyRx, PyMOL and Discovery Studio [122] were used for analyzing the binding affinity, pose and interactions respectively. For MHC alleles which were not available in RCSB PDB, homology modelling was carried out using the SWISS-MODEL server [123]. Ramachandran Plots and Z-scores obtained from the PROCHECK [124] and ProSA [124] servers were used for the validation of the models.

2.8. Prediction of population coverage

The geographical and ethnic diversity of the world encompasses the diversity in distribution of MHC alleles. Therefore, a vaccine's coverage depends upon the coverage of the MHC alleles that its epitopes recognize. We analyzed the combined coverage of our T lymphocyte epitopes using the IEDB population coverage tool with the epitopes and their corresponding MHC class I and class II alleles as the input [125].

2.9. Designing the vaccine construct

A highly-immunogenic mRNA vaccine construct requires the presence of five main elements in the Open Reading Frame (ORF) - 1. Kozak sequence 2. Epitopes 3. Adjuvant 4. Linkers (or spacers) and 5. Stop codon. The start codon should be part of a Kozak sequence [126] while the sequence surrounding the stop codon may be optimized [127]. The criteria used in this study for an epitope to be included in the vaccine construct are antigenicity, non-allergenicity, non-toxicity and cytokine-inducing properties (for HTLs only). Along with appropriate antigenic epitopes, a strong adjuvant can boost the adaptive immune response [50,128,129]. In our design, co-stimulatory molecule CD40 ligand (CD40L) has been added to the vaccine construct since its inclusion was previously reported to be of significant impact and promise [58]. CD40L is able to activate professional Antigen Presenting Cells (pAPCs) [130]. For our purpose, CD40L sequence was retrieved from the UniProt database (UniProt ID: P29965) [131]. Selection of an appropriate epitope-specific linker (e.g., flexible, rigid, cleavable) is an essential step in designing an immunogenic multi-epitope vaccine so that the domains can work independently avoiding interaction and interference between them [132,133]. We chose linkers based on their length and

rigidity-flexibility properties and in accordance with some previous studies [68,134–141]. However, the precise order and position of the epitopes and spacers need to be elucidated through experimental evidences.

The epitopes and the linkers have been combined in the following ways-

- The adjuvant and the HTL epitopes were combined together by GPGPG linkers.
- HTL and LBL epitopes were linked by (EAAK)₂.
- Intra-LBL epitopes were spaced using (EAAK)₂ or (EAAK)₂E.
- LBL and CTL epitopes were linked by AAY.
- Intra-CTL epitopes were combined using AAY linkers.

For increased antigen presentation, sequences for two more elements have been reported to be useful, they are - 1. Signal peptide (for secretion of translated epitopes that need to move out of the cell) and 2. MHC I-targeting domain (MITD) (for directing CTL epitopes to MHC-I compartment of the endoplasmic reticulum) [142–145]. Therefore, we included tissue Plasminogen Activator (tPA) secretory signal sequence and MITD in the 5' and 3' region of the ORF respectively. The sequences for tPA (UniProt ID: P00750) and MITD (UniProt ID: Q8WV92) were retrieved from the UniProt database. Instability being a major concern for mRNA based therapeutics, having the elements that are typically found in eukaryotic mRNAs is crucial [146,147]. So, the incorporation of sequences for 5' cap, poly(A) tail, and 5' and 3' Untranslated Regions (UTRs) was necessary. The length of the poly (A) tail holds significance, since too long or too short tails are associated with translation inefficiency [148,149]. We proposed the length of the poly (A) tail to be 120–150 bases long as it is considered to be optimum by several earlier studies [150–152]. Poly (A) tails are found to work synergistically with 5' m⁷G cap sequences [153]. Combination of β globin 5'-UTR and α globin 3'-UTR being known to stabilize mRNAs [154], we included those in our vaccine design.

2.10. Prediction of antigenicity, allergenicity, toxicity and physicochemical properties of the vaccine construct

For predicting different properties of the vaccine construct, we used the translated peptide form of mRNA vaccine i.e. the single-letter amino acid sequence of the translated form of the ORF as the input. However, tPA and MITD sequences were excluded as they were supposed to be cleaved while entering the secretory pathway and the MHC I pathway respectively. As antigenicity determines the ability of an antigen to evoke an immune response and memory cell formation, the vaccine candidate should be highly antigenic in nature. Therefore, the antigenicity of the vaccine construct was predicted with Vaxijen 2.0 server [96] and ANTIGENpro server [155]. Both of the methods being alignment-free, Vaxijen 2.0 works based on various physicochemical characteristics of the protein, whereas ANTIGENpro is a microarray analysis data based server using machine learning algorithms. To predict whether the vaccine construct was allergenic or not, we used AllerTOP 2.0 server [95]. AllerTOP 2.0 predicts allergenicity based on a method using auto cross-covariance (ACC) transformation of protein sequences into uniform equal-length vector. Toxicity of the vaccine construct was predicted using the ToxinPred server [94]. Various physicochemical features such as amino acid composition, molecular weight, theoretical Isoelectric point (pI), Instability Index (II), Aliphatic Index (AI), and Grand Average of Hydropathicity (GRAVY) were assessed by using the online web server ProtParam [156].

Fig. 2. Multiple sequence alignment of S protein sequences. The epitope sequences selected for vaccine design have been identified by boxes. None of them apparently contains any mutation.

Table 2

Selected T lymphocyte epitopes (CTL + HTL epitopes) and their corresponding MHC alleles.

CTL epitopes	MHC I binding alleles
RQIAPGQTG	HLA-B*15:01, HLA-A*32:07, HLA-B*48:01, HLA-B*15:01
VVFLHVTYV	HLA-C*06:02, HLA-A*02:03, HLA-A*02:06, HLA-A*68:02, HLA-C*07:01, HLA-A*69:01, HLA-A*02:19, HLA-A*02:01, HLA-A*02:11, HLA-A*68:23, HLA-A*02:16, HLA-A*02:02
GVVFLHVTY	HLA-A*29:02, HLA-A*80:01, HLA-A*66:01, HLA-A*32:01
GQTGKIADY	HLA-A*30:02
QLTPTWRVY	HLA-A*29:02, HLA-A*80:01
IAIVMTIM	HLA-B*46:01, HLA-B*58:01, HLA-B*51:01, HLA-B*15:17, HLA-B*53:01, HLA-B*35:01, HLA-C*03:03, HLA-B*57:01
HTL epitopes	MHC II binding alleles
DLPIGINITRFQTL	HLA-DRB1*04:02

Table 3

CTL and HTL epitopes and their corresponding MHC alleles chosen for docking analysis.

T lymphocyte type	Epitope sequence	MHC alleles
CTL	RQIAPGQTG	HLA-B*15:01
	VVFLHVTYV	HLA-C*06:02
	IAIVMTIM	HLA-B*46:01
	QLTPTWRVY	HLA-A*29:02
	GQTGKIADY	HLA-A*30:02
	GVVFLHVTY	HLA-A*32:01
HTL	DLPIGINITRFQTL	HLA-DRB1*04:02

2.11. In silico immune simulation

For estimation of the real-life immunogenic profile of the multi-epitope mRNA vaccine, *in silico* immune simulation was carried out using the C-ImmSim server [157]. For the prediction of epitopes and immune interactions, this simulator uses Position-specific Scoring Matrix (PSSM) and machine learning, respectively. According to most vaccines currently in use, the minimum recommended interval between the first and second dose is 4 weeks [158]. For our immune simulation, three injections, each containing 1000 vaccine construct units, were administered four weeks apart. C-ImmSim server uses a “time-step” scale for calculating durations of simulations. In this scale, each time step is equivalent of 8 h in real life. The total number of time steps for simulation was set at 1050 with the points of the three injections were set at time step 1, 84, and 168 respectively. Rest of the parameters was set at default.

3. Results

3.1. Prediction and assessment of CTL epitopes

NetCTL v1.2 server predicted a total of 269 unique CTL epitopes for 12 MHC class I supertypes. 145 of them had been predicted to be positive in terms of immunogenicity by the IEDB class I immunogenicity tool. Out of these 145 epitopes, all had been found to be non-toxic and

79 to be non-allergenic by the ToxinPred and AllerTOP 2.0 servers respectively. Vaxijen analysis of the 79 immunogenic, non-toxic, and non-allergenic epitopes revealed only 36 epitopes to be successful of crossing the antigenicity threshold of 0.5. Out of these 36 epitopes, most antigenic 6 (RQIAPGQTG, VVFLHVTYV, GVVFLHVTY, GQTGKIADY, QLTPTWRVY, IAIVMTIM) had been selected for vaccine construction (Table 1). The IEDB MHC-I allele binding prediction tool returned 192 epitopes within the ≤ 2 percentile rank.

3.2. Prediction and assessment of HTL epitopes

The IEDB MHC-II allele binding prediction tool returned 82 unique epitopes that recognized 119 alleles in total within the ≤ 0.25 percentile rank. Among them, 23 epitopes met the Vaxijen threshold (≥ 0.5) for antigenicity. All of the 23 antigenic epitopes had been found to be non-toxic by the ToxinPred server. Only 6 of them had been considered as non-allergenic by the AllerTOP 2.0 server. After considering the IFN- γ , IL-4 and IL-10 inducibility using the IFNepitope, IL4pred, and IL10pred servers respectively, only 1 epitope (DLPIGINITRFQTL) was left which had satisfied all the criteria (Table 1).

3.3. Prediction and assessment of LBL epitopes

iBCE-EL server predicted 117 probable LBL epitopes. Among them, 54 met the Vaxijen criteria (≥ 0.5) for being antigenic. All 54 of these epitopes had been predicted to be non-toxic by ToxinPred server and 24 of them had been predicted to be non-allergenic by AllerTOP 2.0 server. Out of the 24, the most antigenic 6 epitopes (GVSPKLNLDLFC, IAPGQTGKIADY, QIAPGQTGKIAD, LVDLPIGINITR, DLPIGINITRFQ, PLVDLPIGINIT) had been selected for the construction of the vaccine (Table 1).

3.4. Multiple sequence alignment of S protein sequences

Clustal Omega and MView multiple alignment viewer found zero mutations within our selected 13 epitopes in 200 SARS-CoV-2 S proteins (Fig. 2).


3.5. Molecular docking between T lymphocyte epitopes and MHC alleles

7 T lymphocyte epitopes recognized 32 MHC alleles in total. With the exception of only two epitopes (GQTGKIADY and DLPIGINITRFQTL) the rest had more than one binding alleles. Some had even as high as 8 (IAIVMTIM) or 12 (VVFLHVTYV) alleles (Table 2). Out of these 7 epitopes and their 32 allelic partners, we decided to perform molecular docking between each epitope and one of their corresponding alleles for a representative docking analysis. Table 3 shows the T lymphocyte epitopes and their MHC alleles chosen for docking. Among the 7 MHC alleles 3 had their crystallographic structures deposited at RCSB PDB. These 3 alleles and their PDB IDs were- HLA-B*15:01 (PDB ID- 5V4M) [159], HLA-C*06:02 (PDB ID- 5W6A) [160], and HLA-B*46:01 (PDB ID- 4LCY) [161]. The rest 4 alleles (HLA-A*29:02, HLA-A*30:02, HLA-A*32:01, HLA-DRB1*04:02) were modelled using SWISS-MODEL. From the validation data of the homology models of MHC alleles whose

Table 4

Validation of the homology models.

Quality parameters		MHC alleles			
		HLA-A*29:02	HLA-A*30:02	HLA-A*32:01	HLA-DRB1*04:02
Z score		-8.80	-8.84	-8.76	-5.42
Ramachandran Plot	Residues in most favored regions (%)	93.0	92.2	93.1	94.0
	Residues in additional allowed regions (%)	6.6	7.4	6.5	5.4
	Residues in generously allowed regions (%)	0.0	0.0	0.0	0.6
	Residues in disallowed regions (%)	0.4	0.4	0.4	0.0



(a) HLA-A*29:02 (b) HLA-A*30:02 (c) HLA-A*32:01 (d) HLA-DRB1*04:02. Fig. 3. Ramachandran plots and Z score diagrams of the 3D homology models of MHC alleles.

Table 5
Binding affinity (kcal/mol) between the epitopes and their corresponding MHC alleles.

Ligand	Allele	Binding affinity
VVFLHVTYV	HLA-C*06:02	−9.9
IAIVMTIM	HLA-B*46:01	−8.3
GQTGKIADY	HLA-A*30:02	−7.4
QLTPTWRVY	HLA-A*29:02	−7.2
GVVFLHVTY	HLA-A*32:01	−7.1
RQIAPGQTG	HLA-B*15:01	−6.6
DLPIGINITRFQTL	HLA-DRB1*04:02	−3.7

structures were not available in RCSB PDB, it is obvious that in case of all 4 alleles over 90% residues belonged to the most favored regions in the Ramachandran plot. They have also demonstrated pretty decent Z scores (Table 4). Ramachandran plots and Z score diagrams revealed that most of the amino acids of the homology models fell within the desired zones (Fig. 3). Table 5 shows the molecular docking results obtained from AutoDock Vina in terms of binding affinity. The epitope VVFLHVTYV showed the strongest affinity (−9.9 kcal/mol) for its corresponding MHC allele. Docking analysis shows that the epitope VVFLHVTYV nicely fits into the epitope binding cleft of the HLA-C*06:02 molecule (Fig. 4A, B). It has also been revealed that the epitope had 6 types of interactions with various residues of the molecule. The favorable interactions include conventional hydrogen bonds, salt bridges, attractive charge interactions, and hydrophobic interactions. On the contrary, the unfavorable interactions include acceptor-acceptor clashes and positive-positive charge repulsions (Fig. 5). In terms of number of interactions there were 7 conventional hydrogen bonds, 2 salt bridges, 2 attractive charge interactions, 11 hydrophobic interactions, 1 acceptor-acceptor clashes, and 2 positive-positive charge repulsions. The length of the bonds ranged from 2.06 to 5.48 Å (Table 6).

3.6. Prediction of population coverage

Combined population coverage of the 7 T lymphocyte epitopes used in this vaccine construction has been the focus of our IEDB population coverage analysis. The distribution of their 32 corresponding MHC alleles in 17 geographical regions and 101 countries found in the IEDB database has been evaluated. Fig. 6 depicts the region-wise coverage of the alleles. The global coverage of our vaccine stands at 82.25%. European, North American and African regions showed some of the highest regional coverage while Central America and Oceania region showed some of the least. In terms of country-specific coverage, European and African countries have topped the list. Since the beginning of the COVID-19 outbreak, Italy, Spain, France, and the United States have

been the hardest hit countries in the world till April 2020. So we were especially interested in seeing how our vaccine coverage did with respect to these countries. Our IEDB analysis showed that the vaccine would cover 89.07%, 87.43%, 89.64%, and 85.65% of the population of Italy, Spain, France and the United States respectively.

3.7. Vaccine construct design

The final entire construct of the vaccine contained the following elements in order from the N-terminal to C-terminal direction:

5'm⁷G Cap – 5'UTR – Kozak sequence – tPA (Signal peptide) – CD40L (Adjuvant) – GPGPG linker – HTL epitope – EAAKEAAK linker – LBL epitope – EAAKEAAK linker – LBL epitope – EAAKEAAK linker – LBL epitope – EAAKEAAK linker – LBL epitope – EAAKEAAK linker – LBL epitope – AAY linker – CTL epitope – AAY linker – CTL epitope – AAY linker – CTL epitope – AAY linker – CTL epitope – AAY linker – CTL epitope – AAY linker – CTL epitope – AAY linker – MITD sequence – Stop codon – 3'UTR – Poly (A) tail.

The proposed mechanism of synthesis, delivery and action of our vaccine has been presented in Fig. 7.

3.8. Antigenicity, allergenicity, toxicity and physicochemical evaluation of the vaccine construct

Results of the antigenicity, allergenicity, toxicity and physicochemical analyses have been listed in Table 7.

Vaxigen and ANTIGENpro both predicted the vaccine to be antigenic with scores of 0.6547 and 0.8504 respectively. AllerTOP predicted the vaccine to be non-allergic. ToxinPred revealed it to be non-toxic. The ProtParam server calculated the molecular weight of the construct as ~52 kDa, while 7.59 pI indicated the vaccine construct to be close to neutral in nature. Total number of amino acids were 478, while the number of negatively and positively charged residues were similar (47 and 48 respectively). In terms of instability, the II was computed to be 32.08, implying that the construct would retain its stability after expression (II of >40 indicates instability). The AI was calculated as 90.33, indicating the construct to be thermostable. The Grand Average of Hydropathicity (GRAVY) was calculated to be negative (−0.064), which indicated the hydrophilic nature of the vaccine. Based on these results, this multi-epitope mRNA vaccine construct can be predicted as a potential vaccine candidate.

3.9. Evaluation of the simulated immune response against the vaccine

As expected, the secondary and tertiary responses were higher than the primary response (Fig. 8). Primarily, high concentrations of Immunoglobulin (Ig) M compared to IgG were detected. In both the




Fig. 4. Docking between the epitope VVFLHVTYV and its corresponding MHC allele, HLA-C*06:02 (A) Surface view of HLA-C*06:02 around ball and stick model of VVFLHVTYV (B) Cartoon representation of HLA-C*06:02 and ball and stick model of VVFLHVTYV.




Fig. 5. Various interactions and bond length (in angstrom) between the epitope VVFLHVTYV and the residues of its corresponding MHC allele, HLA-C*06:02 (A) Conventional hydrogen bonds (B) Hydrophobic interactions (C) Salt bridge, attractive charge interactions (D) Positive-positive repulsion (E) acceptor-acceptor clash.

secondary and tertiary responses, typical high levels of immunoglobulin activities (*i.e.*, IgG1 + IgG2, IgM, and IgG + IgM antibodies) were evident with concomitant antigen reduction. This indicates the emergence of immunological memory and thereby proficient immunity upon subsequent exposures of the antigen. Moreover, several B-cell isotypes were observed to be existent for a long period of time, suggesting the potential for isotype switching and memory formation. A similarly

elevated response was observed in the CTL and HTL populations with their respective memory development. Additionally, an increase in macrophage activity was observed while dendritic cell activity was found to be consistent. High levels of IFN- γ and IL-2 were also obvious. Besides, components of the innate immune system (*e.g.* epithelial cell) were also active. Furthermore, a lower Simpson index (D) indicated a possibility of a variety of immune responses.

Table 6

Docking output between the epitope VVFLHVTYV and HLA-C*06:02 in terms of interactions.

Conventional hydrogen bonds	Salt bridge	Charge-Charge interactions	Hydrophobic interactions	Acceptor-acceptor clash	Positive-Positive repulsion
Gln70 (2.36), Asn77 (2.30), Asn77 (2.06), Trp147 (2.49), Trp156 (2.69), Thr163 (2.52), Trp167 (2.67)	Lys66 (2.98), Lys66 (3.00)	Lys66 (2.98), Lys66 (3.00)	Arg69 (4.93), Ala73 (4.56), Trp97 (3.54), Trp97(4.15), Tyr99 (4.65), Trp156 (5.28), Trp156 (5.48), Tyr159 (4.65), Lys80 (5.47), Leu81 (4.95), Tyr123 (5.32)	Tyr99 (2.87)	Lys80 (4.70), Lys146 (4.60)




Fig. 6. Population coverage of the selected T lymphocyte epitopes. Globally it covers 82.25% of the world's population. The highest and lowest areas of coverage are East Africa (87.78%) and Central America (7.16%) respectively.

4. Discussion

Since the first successful case of mRNA therapeutics in 1990, mRNA vaccines such as those against HIV-1, Zika, rabies, influenza virus *etc.* have represented a versatile and highly effective subset of vaccine candidates [56,162–167]. Despite hurdles like instability of mRNA due to degradation by ubiquitous RNases [59] and inherent immunogenicity due to recognition by innate immune sensors [60,168–170], mRNA vaccine technology has made great progress.

Vaccines are capable of providing immunological memory that persists for several years to several decades [171–173]. Stimulation of both B and T lymphocyte mediated immune responses is considered crucial for any successful vaccination strategy since it is able to provide a faster and more efficient immune response when the host encounters the target pathogen in the future [174]. The goal of vaccination is to trick the body into thinking that it has been attacked by a pathogen and so generate an immune response that leads to the production of memory B and T lymphocytes [175,176]. Generation of effector and memory B and T lymphocytes depends upon the successful recognition of specific target antigens, more specifically, parts of the specific antigens called epitopes. Therefore, it is of great interest to predict B and T lymphocyte epitopes on target antigens when it comes to designing vaccines [177].

CTL mediated cytotoxic activity is a crucial part of the immune response to viral infections. Virus infected cells degrade some of the viral proteins and present them to the CTLs in combination with MHC class I molecules. Recognition of degraded parts of viral proteins called epitopes by CTLs leads to the killing of infected cells through the release of cytotoxic granules [178]. Filtering through various parameters, 6 CTL epitopes have been extracted in this study for construction of a vaccine against SARS-CoV-2 (Table 1).

Antigen-presenting cells display viral particles to HTLs in combination with MHC class II molecules which leads to the activation of HTLs. Upon recognition of the epitopes, the HTLs secrete a wide range of cytokines and chemokines such as IFN- γ , IL-4, IL-10 *etc.* which play diverse roles in the immune response against the invaders [179–182]. Once the

antigens are cleared, most effector T lymphocytes (meaning CTLs and HTLs) perish but a small population of them survive this phase and make up the reservoir of memory T cells [183–185]. Based on our analysis, one HTL epitope was selected for vaccine construction (Table 1).

Using B cell receptors which are basically membrane-bound immunoglobulins, B lymphocytes bind to antigenic epitopes found on the surface of target cells and subsequently internalize, process and present them to T cells [186]. The processed epitopes are presented in combination with MHC class II on the surface of B lymphocytes and are recognized by HTLs possessing a cognate T-cell Receptor (TCR). This leads to the differentiation of B lymphocytes into antibody secreting plasma cells [187–189]. These antibodies are extremely important in neutralizing pathogens [190]. Alternatively, the activated B lymphocytes might initiate germ line center reactions that leads to the generation of memory B cells and long lived plasma cells [191]. In this study, 6 LBLs have been identified as suitable for including in the vaccine construct (Table 1).

Primarily, we used the “2019-nCoV WHU01” strain for epitope prediction. But SARS-CoV-2 being an RNA virus additional mutations are unavoidable [192]. To address this situation, we conducted multiple sequence alignment of randomly selected 200 SARS-CoV-2 S proteins from all over the world covering all but one (Antarctica) continents. The result showing no mutation in our selected epitope area (Fig. 2) indicates the vaccine design to be efficacious. Since it is an mRNA vaccine, the vaccine construct can be modified following the filtering principle we have employed in case of possible future mutation within the epitope regions.

Molecular docking is a key bioinformatics tool that is widely utilized to predict the binding affinity and pose between a ligand and its corresponding receptor [193–196]. Not just in computational drug design, molecular docking has also become an integral part of vaccine design studies. In immunoinformatics, one crucial use of molecular docking is the simulation of binding between T lymphocyte epitopes and their respective MHC molecules [197–199]. The binding affinity between a receptor and its ligand can be defined by the energy released during




Fig. 7. Proposed mechanism of synthesis, delivery and action of the mRNA vaccine against SARS-CoV-2. At first, the PCR template DNA or linearized plasmid DNA containing the designed vaccine sequences is transcribed *in vitro* in a media containing RNA polymerase and nucleotide phosphates. This results in a mixture of double stranded RNAs and other aberrant products. Therefore, chromatographic purification (such as FPLC) is carried out to obtain the mRNA with desired content and length. After vector-mediated delivery into the body, the mRNA transits to the cytosol. In the cytosol, the cellular translation machinery synthesizes proteins which undergo post-translational modifications, resulting in properly folded, fully functional proteins. The secretory signal and MITD sequences direct the peptides to specific compartments of the endoplasmic reticulum and Golgi body for efficient secretion (LBL) and presentation by MHC-I (HTL) and MHC-II (CTL).

spontaneous bond formation between the two and the lower the energy, the more tightly bound the receptor is to its ligand [200,201]. Our selected 7 T lymphocyte epitopes had 32 corresponding MHC alleles (Table 2). We subjected each of these CTL and HTL epitopes and one of their corresponding alleles to molecular docking (Table 3). 4 out of the 7 alleles of our epitopes did not have their 3 dimensional structures available in RCSB PDB database. Therefore, we had to model these receptor molecules using the SWISS-MODEL server. The quality of the models was judged based on Ramachandran Plots and Z scores. In structural biology, Ramachandran plots are considered as one of the most pivotal

concepts. It categorizes the amino acids of any given 3 dimensional protein structure into 4 groups - amino acids in most favored regions, amino acids in additional allowed regions, amino acids in generously allowed regions, and amino acids in disallowed regions. For any protein model to be considered a good model, over 90% of its amino acids need to be in the most favored regions [202,203]. In our case, all 4 of the models satisfied this condition and so could be considered reliable (Table 4). Another indicator of protein model quality is the Z score. A Z score plot describes how a model compares with experimentally determined protein structures of similar size from different sources (X-

Table 7

Antigenic, allergenic, toxicity and physicochemical assessments of the translated protein form of mRNA vaccine translated peptide.

Features	Assessment	Remark
Number of amino acids	478	Suitable
Molecular weight	52,222.98	Average
Chemical formula	C ₂₃₄₆ H ₃₇₁₃ N ₆₁₉ O ₆₉₅ S ₁₆	–
Theoretical pI	7.59	Slightly basic
Total number of negatively charged residues (Asp + Glu)	47	–
Total number of positively charged residues (Arg + Lys)	48	–
Total number of atoms	7389	–
Instability Index (II)	32.08	Stable
Aliphatic index (AI)	90.33	Thermostable
Grand Average of hydropathicity (GRAVY)	−0.064	Hydrophilic
Antigenicity	0.6547 (Vaxijen)	Antigenic
	0.8504 (ANTIGENpro)	Antigenic
Allergenicity	Probable non-allergen (AllerTOP 2.0)	Non-allergen
Toxicity	Non-toxin (ToxinPred)	Non-toxic

ray, NMR) [204]. All our models fell within the acceptable zone in the Z score plots (Fig. 3). Based on the molecular docking of our selected epitopes with their corresponding alleles, we have found out that the epitope VVFLHVTYV possessed the highest binding affinity for its corresponding MHC allele, HLA-C*06:02 (Table 5) and exhibited a wide array of interactions (Table 6). It bound successfully to the epitope binding pocket of HLA-C*06:02 (Fig. 4) and took part in bond formation with neighboring residues (Fig. 5).

In vaccine design, careful consideration needs to be put on the population coverage of the T lymphocyte epitopes. The presence of over a thousand human MHC alleles around the globe is a factor that must be addressed because only those who possess a particular MHC allele recognizing the epitopes in our vaccine construct will launch an immune response when exposed to the vaccine [125]. In this study, the combined coverage of the CTL and HTL epitopes was checked to predict the effectiveness of our vaccine across various geographical regions of the world. The IEDB population coverage tool predicted a decent worldwide coverage (Fig. 6) while higher degree of coverage was predicted for countries that saw the most devastating effects of the SARS-CoV-2 pandemic.

While developing an mRNA-vaccine, important factors such as mRNA manufacturing, quality control, formulation, immunological and physicochemical properties of the vaccine as well as the translated form of the peptide come into question. For successful cellular uptake, immune stimulation and induction of long-term memory, emphasis should be put on designing the vaccine construct in a way that avoids interaction with RNA-sensors. For ensuring Good Manufacturing Practice (GMP), some perspectives such as cost-effectiveness are major issues. Industrially, mRNA is obtained by *in vitro* transcription of DNA (linearized plasmid DNA or PCR template) containing a recognition site for RNA polymerase attachment [205–207]. This mRNA preparation contains double-stranded RNA (dsRNA) contaminants [208], which being a potent Pathogen-associated Molecular Pattern (PAMP) result in robust type I interferon production. This leads to the inhibition of translation [209] and the degradation of cellular mRNA and ribosomal RNA [210]. To solve this problem, purification of mRNA using High-performance Liquid Chromatography (HPLC) has resulted in increase of translation upto 1000-fold [208]. A chromatographic purification technology named PUREmessenger has obtained highly pure mRNA transcripts by elimination of contaminating shorter or longer transcripts [55]. However, the highest level of protein production has been reported when the mRNA was both HPLC-purified and nucleoside-modified [208]. Apparently, the transcription step in mRNA vaccines makes the production more expensive compared to DNA vaccines. But










in practice, it is actually less costly in the long run because of higher transfection rate.

Developing an effective and safe adjuvant requires an intricate balance between immunogenicity and safety because of the risk of undesired level of host immune system activation and inflammatory responses in some cases. Several approaches showed promise in this aspect, such as those using protamine and cytokine granulocyte macrophage colony-stimulating factor (GM-CSF) [57,211–218]. Besides, when administered naked, mRNA itself has been reported to be self-adjuvanting [57]. But *in vivo* degradation makes it a poor approach. We included co-stimulatory molecule CD40L considering its ability to stimulate pAPCs and thereby induce immune response molecules [58,130]. However, excluding the adjuvant would certainly reduce time and costs. Therefore, further experimentation can tell whether the inclusion was absolutely necessary. Optimum spacers with a balance between flexibility and rigidity also contribute to the proper functioning of the mRNA vaccine by preventing inter-domain interactions. [132,133]

During *in vitro* transcription, mRNA can be capped co-transcriptionally using enzymatic action of vaccinia virus capping complex [219,220] or “Anti-reverse” Cap Analogs (ARCs) [221–224]. Poly (A) tails have been found to work synergistically with 5' m⁷G cap sequences with optimum length being 120–150 base pairs [147,150–153]. For increased translation and stability, 5' and 3' UTRs need to flank the mRNA ORF [225–227]. Globin UTRs are commonly used for *in vitro* transcription of mRNA. Incorporation of both the Xenopus β globin 5' and 3'-UTRs have been found to increase translational efficiency by about 1000-fold [228]. We decided to use a combination of β globin 5'-UTR and α globin 3'-UTR, which had been known to stabilize mRNAs [154,229]. Sequences surrounding the stop codon might be optimized and the Kozak sequence also demands attention [126,127].

Inclusion of sequences for a secretory signal as well as those that contain directional information regarding specific compartments of endoplasmic reticulum (e.g. MHC I), have been associated with higher efficiency of mRNA and DNA based vaccines [143–145]. Enrichment of G: C content has been shown to increase steady-state mRNA levels *in vitro* [230] and protein expression *in vivo* [231]. In some species, codon bias i.e. replacement of rare codons with frequently used synonymous codons have been associated with both efficiency [232] and probable adverse effect [230,233,234]. But it does not correlate with tRNA levels and gene expression in humans [235,236]. Therefore, it has been avoided in our mRNA vaccine designing. Incorporation of naturally occurring chemically modified nucleosides, such as pseudouridine [237], and 1-methylpseudouridine [238] has been reported to enhance *in vitro* translation. Its efficacy is based on escaping Toll-like Receptor (TLR) 7, 8 and other innate immune sensors [239,240] and thus reducing type I interferon signaling [241]. However, whether it can have an impact upon *in vivo* translation remains to be tested.

mRNA formulation and administration are also crucial factors for antigen expression. Recently, Lipid Nanoparticle (LNP) has emerged as a promising vector for mRNA vaccines. Route of administration is also a contributing factor here. Intramuscular and intradermal delivery of mRNA-LNPs has been shown to result in three-fold more persistent protein expression than intravenous delivery. As sustained antigen availability during vaccination drives higher antibody titres and pronounced immune responses, higher half-life can contribute to higher potency of the vaccine. [63,164,242–244]. In the case of our vaccine, intranasal administration is a probable option, as the virus has been reported to infect the respiratory tract. After incorporation into the cytosol, mRNA comes into contact of the cytosolic translation complex. After translation and post-translational modifications, the vaccine gets ready to generate immune response (Fig. 7). The translated form of our mRNA construct was predicted to be almost neutral, stable, highly antigenic, non-allergenic and hydrophilic, thermostable in nature by various *in silico* tools making it a potential candidate for a vaccine.



In silico immune response simulation showed an overall increase in immune responses following repeated exposure to the antigen (Fig. 8). The higher B and T-cell activity and lasting of B cell memory for several months indicated humoral immunity; which is essential for complementing the immune response. High levels of IFN- γ and IL-2 production during repeated exposure indicated cell mediated immune response. The cytokine IFN- γ being involved in B-cell proliferation and Ig isotype switching [245,246], it can support a humoral response as well. Moderate levels of IL-10 and IL-4 activity were observed since IL-10 and IL-4 positive HTL epitopes were selected and incorporated into the vaccine construct. Dendritic cell and macrophage activities and Simson index were found to be up to the mark. This profile of the vaccine suggests immune memory development and, thereby, natural immune protection against SARS-CoV-2.

Instead of beginning with the laboratory-based expensive and time-consuming methods, immunoinformatics provides the advantage of low cost and fast identification and screening of epitopes and designing a vaccine. In the face of worldwide transmission of the COVID-19 pandemic at an alarming rate, rapid and high-yield technologies like mRNA vaccine production is the one to meet the challenge. Our immunoinformatics based approach for designing a multi-epitope mRNA vaccine against the spike glycoprotein of SARS-CoV-2 have demonstrated that this novel vaccine candidate can be a useful tool in mankind's arsenal against the deadly virus. This can only come to fruition after further validation of its performance *in vitro* and *in vivo* through coordinated action between the relevant quarters.

Author contributions

Samia Sultana Lira and Ishtiaque Ahammad contributed equally to this research work. More specifically, Samia Sultana Lira designed the mRNA vaccine construct, performed antigenicity, allergenicity, toxicity, physicochemical assessment, and immune simulation of the constructed vaccine, and wrote the related parts in material and methods, results and discussion sections in addition to writing the introduction section of the manuscript. Ishtiaque Ahammad predicted and assessed the CTL, HTL and LBL epitopes, performed homology modelling and molecular docking, population coverage analysis and wrote the related parts in material and methods, results and discussion sections of the manuscript. Both authors contributed equally in writing the abstract, conducting multiple sequence alignment, preparing the figures and editing the manuscript.

Declaration of competing interest

None.

Acknowledgement

The authors would like to acknowledge the contributions of Mr. Md. Shamsul Arefin Prince of North South University, Dhaka, Bangladesh who is not listed as an author for his outstanding support in conducting this study. He kept the authors well informed about the latest developments in the rapidly evolving SARS-CoV-2 research field and these pieces of information had their reflection in this work. Throughout the project he provided consultation regarding the core concepts of the study and helped overcome a number of obstacles. The authors are expressing their sincere gratitude to Mr. Md. Shamsul Arefin Prince for his contributions.

Funding information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- [1] WHO coronavirus disease (COVID-19) dashboard, covid19.who.int, [Online]. Available https://covid19.who.int/?gclid=Cj0KCQjwujz3BRDARIsAMg-HxWebhEahKiyYjHOqW8IGbRG0kZrUegaFNBzj0n4Txg_6eQBlqgWnlaAuWoEALw_wcB. (Accessed 15 June 2020).
- [2] F. Wu, et al., A new coronavirus associated with human respiratory disease in China, *Nature* 579 (7798) (2020) 265–269 Mar.
- [3] Naming the coronavirus disease (COVID-19) and the virus that causes it, www.who.int, [Online]. Available [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it). (Accessed 16 June 2020).
- [4] A.E. Gorbalenya, et al., The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, *Nat. Microbiol.* (2020) 1–9 Mar.
- [5] A.R. Fehr, S. Perlman, Coronaviruses: an overview of their replication and pathogenesis, *Coronaviruses: Methods and Protocols*, Springer New York 2015, pp. 1–23.
- [6] E. de Wit, N. van Doremalen, D. Falzarano, V.J. Munster, SARS and MERS: recent insights into emerging coronaviruses, *Nat. Rev. Microbiol.* 14 (8) (Jun. 2016) 523–534.
- [7] Y. Hu, L. SHEN, Z. XU, J. Zhou, H. Zhou, SARS-CoV-2 May Persist in Digestive Tract Longer Than Respiratory Tract, Feb. 2020.
- [8] L. Lin, et al., Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection, *Gut* 69 (6) (2020) 997–1001 Apr.
- [9] S.H. Wong, R.N. Lui, J.J. Sung, Covid-19 and the digestive system, *J. Gastroenterol. Hepatol.* 35 (5) (2020) 744–748 May.
- [10] J. Wang, et al., ACE2 Expression by Colonic Epithelial Cells Is Associated With Viral Infection, Immunity and Energy Metabolism, Feb. 2020.
- [11] C. Huang, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, *Lancet* 395 (10223) (2020) 497–506 Feb.
- [12] R. Woelfel, et al., Clinical Presentation and Virological Assessment of Hospitalized Cases of Coronavirus Disease 2019 in a Travel-associated Transmission Cluster, Mar. 2020.
- [13] Y. Yang, et al., Epidemiological and Clinical Features of the 2019 Novel Coronavirus Outbreak in China, Feb. 2020.
- [14] N. Zhu, et al., A novel coronavirus from patients with pneumonia in China, 2019, *N. Engl. J. Med.* 382 (2020) 727–733 Feb.
- [15] Q. Li, et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, *N. Engl. J. Med.* (2020) <https://doi.org/10.1056/NEJMoa2001316> p.
- [16] W. Guan, et al., Clinical Characteristics of 2019 Novel Coronavirus Infection in China, Feb. 2020.
- [17] W. Wang, J. Tang, F. Wei, Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China, *J. Med. Virol.* 92 (4) (2020) 441–447 Apr.
- [18] C.-C. Lai, T.-P. Shih, W.-C. Ko, H.-J. Tang, P.-R. Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, *Int. J. Antimicrob. Agents* 55 (3) (2020) 105924 Mar.
- [19] Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19), www.who.int, [Online]. Available [https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)). (Accessed 15 June 2020).
- [20] Y. Chen, Q. Liu, D. Guo, Emerging coronaviruses: genome structure, replication, and pathogenesis, *J. Med. Virol.* 92 (4) (2020) 418–423 Feb.
- [21] L. Chen, et al., RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak, *Emerging Microbes & Infections* 9 (1) (2020) 313–319 Jan.
- [22] J. Ziebuhr, Molecular biology of severe acute respiratory syndrome coronavirus, *Curr. Opin. Microbiol.* 7 (4) (2004) 412–419 Aug.
- [23] A. Wu, et al., Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China, *Cell Host Microbe* 27 (3) (2020) 325–328 Mar.
- [24] L.D. Eckerle, et al., Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing, *PLoS Pathog.* 6 (5) (2010), e1000896. May.
- [25] N.S. Ogando, F. Ferron, E. Decroly, B. Canard, C.C. Posthuma, E.J. Snijder, The curious case of the nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity, *Front. Microbiol.* 10 (2019) Aug.
- [26] E.C. Smith, H. Blanc, M. Vignuzzi, M.R. Denison, Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proof-reading and potential therapeutics, *PLoS Pathog.* 9 (8) (2013), e1003565. Aug.
- [27] F. Li, Structure of SARS coronavirus spike receptor-binding domain complexed with receptor, *Science* 309 (5742) (2005) 1864–1868 Sep.

Fig. 8. *In silico* simulation of immune response against the mRNA vaccine. (A) Immunoglobulin production in response to antigen injection (B) B cell population after three injections (C) B cell population per state (D) Helper T cell population (E) Helper T cell population per state (F) Cytotoxic T cell population per state (G) Macrophage population per state (H) Dendritic cell population per state (I) Production of cytokines and interleukins with Simpson index of the immune response.

- [28] M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses, *Nat. Microbiol.* 5 (2020) 562–569 Feb.
- [29] G. Lu, et al., Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26, *Nature* 500 (7461) (2013) 227–231 Jul.
- [30] P. Zhou, et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, *Nature* 579 (2020) 270–273 Feb.
- [31] M. Hoffmann, H. Kleine-Weber, N. Krüger, M. Müller, C. Drosten, S. Pöhlmann, The Novel Coronavirus 2019 (2019-nCoV) Uses the SARS-coronavirus Receptor ACE2 and the Cellular Protease TMPRSS2 for Entry Into Target Cells, *Jan.* 2020.
- [32] J. Luan, Y. Lu, X. Jin, L. Zhang, Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection, *Biochem. Biophys. Res. Commun.* 526 (1) (2020) 165–169 May.
- [33] B. Coutard, C. Valle, X. de Lamballerie, B. Canard, N.G. Seidah, E. Decroly, The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, *Antivir. Res.* 176 (2020), 104742. Apr.
- [34] I. Hamming, W. Timens, M. Bulthuis, A. Lely, G. Navis, H. van Goor, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, *J. Pathol.* 203 (2) (2004) 631–637 Mar.
- [35] X. Zou, K. Chen, J. Zou, P. Han, J. Hao, Z. Han, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, *Frontiers of Medicine* 14 (2) (2020) 185–192 Apr.
- [36] J.J. Koehorst, J.C.J. van Dam, E. Saccenti, V.A.P. Martins dos Santos, M. Suarez-Diez, P.J. Schaap, SAPP: functional genome annotation and analysis through a semantic framework using FAIR principles, *Bioinformatics* 34 (8) (2017) 1401–1403 Nov.
- [37] F. Amanat, F. Krammer, SARS-CoV-2 vaccines: status report, *Immunity* 52 (4) (2020) 583–589 Apr.
- [38] B. Delmas, H. Laude, Assembly of coronavirus spike protein into trimers and its role in epitope expression, *J. Virol.* 64 (11) (1990) 5367–5375.
- [39] D.R. Beniac, A. Andonov, E. Grudeski, T.F. Booth, Architecture of the SARS coronavirus prefusion spike, *Nat. Struct. Mol. Biol.* 13 (8) (2006) 751–752 Jul.
- [40] L. Du, Y. Yang, Y. Zhou, L. Lu, F. Li, S. Jiang, MERS-CoV spike protein: a key target for antivirals, *Expert Opin. Ther. Targets* 21 (2) (2016) 131–143 Dec.
- [41] L. Lu, et al., Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor, *Nat. Commun.* 5 (1) (2014) Jan.
- [42] L. Du, et al., Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines, *Nat. Commun.* 7 (1) (2016) Nov.
- [43] Y. He, J. Li, S. Heck, S. Lustigman, S. Jiang, Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design, *J. Virol.* 80 (12) (2006) 5757–5767 Jun.
- [44] S. Liu, et al., Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors, *Lancet* 363 (9413) (2004) 938–947 Mar.
- [45] Q. Wang, G. Wong, G. Lu, J. Yan, G.F. Gao, MERS-CoV spike protein: targets for vaccines and therapeutics, *Antivir. Res.* 133 (2016) 165–177 Sep.
- [46] L. Du, Y. He, Y. Zhou, S. Liu, B.-J. Zheng, S. Jiang, The spike protein of SARS-CoV – a target for vaccine and therapeutic development, *Nat. Rev. Microbiol.* 7 (3) (2009) 226–236 Feb.
- [47] A.C. Walls, Y.-J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veesler, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, *Cell* 181 (2) (2020) 281–292 Apr.
- [48] S.A. Plotkin, Vaccines: the fourth century, *Clin. Vaccine Immunol.* 16 (12) (2009) 1709–1719 Sep.
- [49] S. Tandrup Schmidt, C. Foged, K. Smith Korsholm, T. Rades, D. Christensen, Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators, *Pharmaceutics* 8 (1) (2016) 7 Mar.
- [50] W. Li, M.D. Joshi, S. Singhanian, K.H. Ramsey, A.K. Murthy, Peptide vaccine: progress and challenges, *Vaccines* 2 (3) (2014) 515–536 Jul.
- [51] J.J. Suschak, J.A. Williams, C.S. Schmaljohn, Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity, *Human Vaccines & Immunotherapeutics* 13 (12) (2017) 2837–2848 Jun.
- [52] A. Jäschke, M. Helm, RNA sex, *Chem. Biol.* 10 (12) (2003) 1148–1150 Dec.
- [53] A.B. Chetverin, Replicable and recombinogenic RNAs, *FEBS Lett.* 567 (1) (2004) 35–41 Apr.
- [54] S. Pascolo, "Vaccination with messenger RNA," *DNA Vaccines*, pp. 23–40.
- [55] J. Probst, et al., Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent, *Gene Ther.* 14 (15) (2007) 1175–1180 May.
- [56] J. Wolff, et al., Direct gene transfer into mouse muscle in vivo, *Science* 247 (4949) (1990) 1465–1468 Mar.
- [57] M. Fotin-Mleczek, et al., Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity, *J. Immunother.* 34 (1) (2011) 1–15 Jan.
- [58] T. Schlake, A. Thess, M. Fotin-Mleczek, K.-J. Kallen, Developing mRNA-vaccine technologies, *RNA Biol.* 9 (11) (2012) 1319–1330 Nov.
- [59] N.B. Tsui, E.K. Ng, Y.D. Lo, Stability of endogenous and added RNA in blood specimens, serum, and plasma, *Clin. Chem.* 48 (10) (2002) 1647–1653 Oct.
- [60] N. Chen, P. Xia, S. Li, T. Zhang, T.T. Wang, J. Zhu, RNA sensors of the innate immune system and their detection of pathogens, *IUBMB Life* 69 (5) (2017) 297–304 Apr.
- [61] B. Petsch, et al., Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection, *Nat. Biotechnol.* 30 (12) (2012) 1210–1216 Nov.
- [62] A.J. Geall, et al., Nonviral delivery of self-amplifying RNA vaccines, *Proc. Natl. Acad. Sci.* 109 (36) (2012) 14604–14609 Aug.
- [63] N. Pardi, et al., Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination, *Nature* 543 (7644) (2017) 248–251 Feb.
- [64] S. Khalilii, A. Jahangiri, H. Borna, K. Ahmadi Zanoos, J. Amani, Computational vaccinology and epitope vaccine design by immunoinformatics, *Acta Microbiol. Immunol. Hung.* 61 (3) (2014) 285–307 Sep.
- [65] R.R. Maria, C.J. Arturo, J.A. Alicia, M.G. Paulina, A.O. Gerardo, The impact of bioinformatics on vaccine design and development, *Vaccines* (Sep. 2017).
- [66] M. Nosrati, A. Hajizade, S. Nazarian, J. Amani, A. Namvar Vansofla, Y. Tarverzideh, Designing a multi-epitope vaccine for cross-protection against *Shigella* spp: an immunoinformatics and structural vaccinology study, *Mol. Immunol.* 116 (2019) 106–116.
- [67] M. Hasan, et al., Contriving a chimeric polyvalent vaccine to prevent infections caused by herpes simplex virus (type-1 and type-2): an exploratory immunoinformatic approach, *J. Biomol. Struct. Dyn.* (2019) 1–18 Aug.
- [68] N. Hajjibrahmani, N. Nezafat, M. Eslami, M. Negahdaripour, S.S. Rahmatabadi, Y. Ghasemi, Immunoinformatics analysis and in silico designing of a novel multi-epitope peptide vaccine against *Staphylococcus aureus*, *Infect. Genet. Evol.* 48 (2017) 83–94 Mar.
- [69] F. Abdulla, U.K. Adhikari, M.K. Uddin, Exploring T & B-cell epitopes and designing multi-epitope subunit vaccine targeting integration step of HIV-1 lifecycle using immunoinformatics approach, *Microb. Pathog.* 137 (2019), 103791. Dec.
- [70] K.F. Azim, et al., Immunoinformatics approaches for designing a novel multi epitope peptide vaccine against human norovirus (Norwalk virus), *Infect. Genet. Evol.* 74 (2019), 103936. Oct.
- [71] L. Moise, J.A. McMurry, S. Buus, S. Frey, W.D. Martin, A.S. De Groot, In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes, *Vaccine* 27 (46) (2009) 6471–6479 Oct.
- [72] J. Schaefer, Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, *EpiMatrix, Vaccine* 16 (19) (1998) 1880–1884 Nov.
- [73] C.E. Bounds, et al., An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice, *Human Vaccines & Immunotherapeutics* 13 (12) (2017) 2824–2836 Jun.
- [74] S.F. Ahmed, A.A. Quadeer, M.R. McKay, Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies, *Viruses* 12 (3) (2020) 254 Feb.
- [75] A. Grifoni, J. Sidney, Y. Zhang, R.H. Scheuermann, B. Peters, A. Sette, A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2, *Cell Host Microbe* 27 (4) (2020) 671–680.e2 Apr.
- [76] D. Wrapp, et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, *Science* (Feb. 2020) eabb2507.
- [77] X. Tian, et al., Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, *Emerging Microbes & Infections* 9 (1) (2020) 382–385 Jan.
- [78] M. Enayatkhani, et al., Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study, *J. Biomol. Struct. Dyn.* (2020) 1–16 May.
- [79] P. Kalita, A.K. Padhi, K.Y.J. Zhang, T. Tripathi, Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2, *Microb. Pathog.* 145 (2020), 104236. Aug.
- [80] G. Lucchese, Epitopes for a 2019-nCoV vaccine, *Cellular & Molecular Immunology* 17 (5) (2020) 539–540 Feb.
- [81] B. Robson, Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus, *Comput. Biol. Med.* 119 (2020) 103670 Apr.
- [82] B.E. Pickett, et al., ViPR: an open bioinformatics database and analysis resource for virology research, *Nucleic Acids Res.* 40 (D1) (2011) D593–D598 Oct.
- [83] D.A. Benson, et al., GenBank, *Nucleic Acids Res.* 41 (D1) (2012) D36–D42 Nov.
- [84] B. Asquith, A.R. McLean, In vivo CD8+ T cell control of immunodeficiency virus infection in humans and macaques, *Proc. Natl. Acad. Sci.* 104 (15) (2007) 6365–6370 Apr.
- [85] M.K. Maini, et al., The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus infection, *J. Exp. Med.* 191 (8) (2000) 1269–1280 Apr.
- [86] P.J.R. Goulder, D.I. Watkins, HIV and SIV CTL escape: implications for vaccine design, *Nat. Rev. Immunol.* 4 (8) (2004) 630–640 Aug.
- [87] A.J. Leslie, et al., HIV evolution: CTL escape mutation and reversion after transmission, *Nat. Med.* 10 (3) (2004) 282–289 Feb.
- [88] B. Alberts, A. Johnson, J. Lewis, et al., T cells and MHC proteins, *Molecular biology of the cell*, 4th ed Garland Science, New York, 2002. [Online] Available <https://www.ncbi.nlm.nih.gov/books/NBK26926>. (Accessed 26 June 2020).
- [89] S.A. Ali, Y.A. Almofti, K.A. Abd-elrahman, Immunoinformatics approach for multiepitopes vaccine prediction against glycoprotein B of avian infectious laryngotracheitis virus, *Adv. Bioinforma.* 2019 (2019) 1–23 Mar.
- [90] V. Baruah, S. Bose, Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV, *J. Med. Virol.* 92 (5) (2020) 495–500 May.
- [91] K.S. Lata, et al., Exploring leptospiral proteomes to identify potential candidates for vaccine design against leptospirosis using an immunoinformatics approach, *Sci. Rep.* 8 (1) (2018) May.
- [92] M.V. Larsen, C. Lundegaard, K. Lamberth, S. Buus, O. Lund, M. Nielsen, Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction, *BMC Bioinformatics* 8 (1) (2007) Oct.
- [93] J.J.A. Calis, et al., Properties of MHC class I presented peptides that enhance immunogenicity, *PLoS Comput. Biol.* 9 (10) (2013), e1003266. Oct.

- [94] S. Gupta, P. Kapoor, K. Chaudhary, A. Gautam, R. Kumar, G.P.S. Raghava, In silico approach for predicting toxicity of peptides and proteins, *PLoS One* 8 (9) (2013), e73957. Sep.
- [95] I. Dimitrov, I. Bangov, D.R. Flower, I. Doytchinova, AllerTOP v.2—a server for in silico prediction of allergens, *J. Mol. Model.* 20 (6) (2014) May.
- [96] I.A. Doytchinova, D.R. Flower, Vaxijen: a server for prediction of protective antigens, tumour antigens and subunit vaccines, *BMC Bioinformatics* 8 (1) (2007) Jan.
- [97] M. Moutafsi, et al., A consensus epitope prediction approach identifies the breadth of murine T(CD8+)–cell responses to vaccinia virus, *Nat. Biotechnol.* 24 (7) (2006) 817–819.
- [98] T.M. Holling, E. Schooten, P.J. van Den Elsen, Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men, *Hum. Immunol.* 65 (4) (2004) 282–290 Apr.
- [99] H. Zahroh, A. Ma'rup, U.S.F. Tambunan, A.A. Parikesit, Immunoinformatics approach in designing epitope-based vaccine against meningitis-inducing bacteria (*Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b), *Drug Target Insights* 10 (2016) DTLS38458 Jan.
- [100] M. Khan, et al., Immunoinformatics approaches to explore *Helicobacter pylori* proteome (virulence factors) to design B and T cell multi-epitope subunit vaccine, *Sci. Rep.* 9 (1) (2019) Sep.
- [101] R. Kumar Pandey, R. Ojha, A. Mishra, V. Kumar Prajapati, Designing B- and T-cell multi-epitope based subunit vaccine using immunoinformatics approach to control Zika virus infection, *J. Cell. Biochem.* 119 (9) (2018) 7631–7642 Jun.
- [102] P. Wang, et al., Peptide binding predictions for HLA DR, DP and DQ molecules, *BMC Bioinformatics* 11 (1) (2010) 568.
- [103] S.K. Dhanda, P. Vir, G.P. Raghava, Designing of interferon-gamma inducing MHC class-II binders, *Biol. Direct* 8 (1) (2013) Dec.
- [104] S.K. Dhanda, S. Gupta, P. Vir, G.P.S. Raghava, Prediction of IL4 inducing peptides, *Clin. Dev. Immunol.* 2013 (2013) 1–9.
- [105] G. Nagpal, et al., Computer-aided designing of immunosuppressive peptides based on IL-10 inducing potential, *Sci. Rep.* 7 (1) (2017) Feb.
- [106] T. Dörner, A. Radbruch, Antibodies and B cell memory in viral immunity, *Immunity* 27 (3) (2007) 384–392 Sep.
- [107] R.K.G. Do, E. Hatada, H. Lee, M.R. Tourigny, D. Hilbert, S. Chen-Kiang, Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response, *J. Exp. Med.* 192 (7) (2000) 953–964 Sep.
- [108] M. Lechmann, et al., T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus–positive blood donors without viremia, *Hepatology* 24 (4) (Oct. 1996) 790–795.
- [109] A. Cerino, M.U. Mondelli, Identification of an immunodominant B cell epitope on the hepatitis C virus nonstructural region defined by human monoclonal antibodies, *J. Immunol.* 147 (8) (Oct. 1991) 2692–2696.
- [110] M. Lehtinen, M.H. Hibma, G. Stellato, T. Kuoppala, J. Paavonen, Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16, *Biochem. Biophys. Res. Commun.* 209 (2) (1995) 541–546 Apr.
- [111] R.J. Noelle, E.C. Snow, T helper cell-dependent B cell activation, *FASEB J.* 5 (13) (1991) 2770–2776 Oct.
- [112] C.A. P. Travers, M. Walport, and M.J. Shlomchik, “B-cell activation by armed helper T cells,” *Nih.gov*, 2009. [Online]. Available: <https://www.ncbi.nlm.nih.gov/books/NBK27142/>.
- [113] T.A. Ahmad, A.E. Eweida, S.A. Sheweita, B-cell epitope mapping for the design of vaccines and effective diagnostics, *Trials in Vaccinology* 5 (2016) 71–83.
- [114] Y. EL-Manzalawy, D. Dobbs, V. Honavar, Predicting linear B-cell epitopes using string kernels, *Journal of molecular recognition: JMR* 21 (4) (2008) 243–255.
- [115] B. Manavalan, R.G. Govindaraj, T.H. Shin, M.O. Kim, G. Lee, iBCE-EL: a new ensemble learning framework for improved linear B-cell epitope prediction, *Front. Immunol.* 9 (2018) Jul.
- [116] F. Madeira, et al., The EMBL-EBI search and sequence analysis tools APIs in 2019, *Nucleic Acids Res.* 47 (2019).
- [117] H.M. Berman, The protein data bank, *Nucleic Acids Res.* 28 (1) (2000) 235–242 Jan.
- [118] S.K. Burley, et al., RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy, *Nucleic Acids Res.* 47 (D1) (2018) D464–D474 Oct.
- [119] R.E. Rigsby, A.B. Parker, Using the PyMOL application to reinforce visual understanding of protein structure, *Biochem. Mol. Biol. Educ.* 44 (5) (2016) 433–437 May.
- [120] O. Trott, A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, *J. Comput. Chem.* 31 (2) (2010) 455–461 Jan.
- [121] S. Dallakyan, A.J. Olson, Small-molecule library screening by docking with PyRx, *Methods Mol. Biol.* (Dec. 2014) 243–250.
- [122] Dassault Systèmes BIOVIA, Discovery studio modeling environment, p. Release 4.1 Dassault Systèmes, San Diego 2015. [Online]. Available <https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio>. (Accessed 15 June 2020).
- [123] A. Waterhouse, et al., SWISS-MODEL: homology modelling of protein structures and complexes, *Nucleic Acids Res.* 46 (W1) (2018) W296–W303 May.
- [124] R. Laskowski, J.A. Rullmann, M. MacArthur, R. Kaptein, J. Thornton, AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR, *J. Biomol. NMR* 8 (4) (1996) Dec.
- [125] H.H. Bui, J. Sidney, K. Dinh, S. Southwood, M.J. Newman, A. Sette, Predicting population coverage of T-cell epitope-based diagnostics and vaccines, *BMC Bioinformatics* 7 (2006) 153, Mar <https://doi.org/10.1186/1471-2105-7-153>.
- [126] M. Kozak, Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes, *Cell* 44 (2) (1986) 283–292 Jan.
- [127] Q. Liu, Comparative analysis of base biases around the stop codons in six eukaryotes, *Biosystems* 81 (3) (2005) 281–289 Sep.
- [128] B. Pulendran, R. Ahmed, Translating innate immunity into immunological memory: implications for vaccine development, *Cell* 124 (4) (2006) 849–863 Feb.
- [129] A.S. McKee, P. Marrack, Old and new adjuvants, *Curr. Opin. Immunol.* 47 (2017) 44–51 Aug.
- [130] C. Caux, et al., Activation of human dendritic cells through CD40 cross-linking, *J. Exp. Med.* 180 (4) (1994) 1263–1272 Oct.
- [131] UniProt: a worldwide hub of protein knowledge, *Nucleic Acids Res.* 47 (D1) (2018) D506–D515 Nov.
- [132] X. Chen, J.L. Zaro, W.-C. Shen, Fusion protein linkers: property, design and functionality, *Adv. Drug Deliv. Rev.* 65 (10) (2013) 1357–1369 Oct.
- [133] R. Arai, H. Ueda, A. Kitayama, N. Kamiya, T. Nagamune, Design of the linkers which effectively separate domains of a bifunctional fusion protein, *Protein Eng. Des. Sel.* 14 (8) (2001) 529–532 Aug.
- [134] R.K. Pandey, T.K. Bhatt, V.K. Prajapati, Novel Immunoinformatics approaches to design multi-epitope subunit vaccine for malaria by investigating anopheles salivary protein, *Sci. Rep.* 8 (1) (2018) Jan.
- [135] R.A. Shey, et al., In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases, *Sci. Rep.* 9 (1) (2019) Mar.
- [136] L. Michel-Todó, P.A. Reche, P. Bigey, M.-J. Pinazo, J. Gascón, J. Alonso-Padilla, In silico design of an epitope-based vaccine ensemble for Chagas disease, *Front. Immunol.* 10 (2019) Nov.
- [137] S.B. Sayed, Z. Nain, M.S.A. Khan, F. Abdulla, R. Tasmin, U.K. Adhikari, Exploring Lassa virus proteome to design a multi-epitope vaccine through immunoinformatics and immune simulation analyses, *Int. J. Pept. Res. Ther.* (2020) 1–19 Jan.
- [138] T. Farhadi, N. Nezafat, Y. Ghasemi, Z. Karimi, S. Hemmati, N. Erfani, Designing of complex multi-epitope peptide vaccine based on Omgs of *Klebsiella pneumoniae*: an in silico approach, *Int. J. Pept. Res. Ther.* 21 (3) (2015) 325–341 Apr.
- [139] Y. Gu, X. Sun, B. Li, J. Huang, B. Zhan, X. Zhu, Vaccination with a paramyosin-based multi-epitope vaccine elicits significant protective immunity against *Trichinella spiralis* infection in mice, *Front. Microbiol.* 8 (2017) Aug.
- [140] N. Nezafat, Z. Karimi, M. Eslami, M. Mohkam, S. Zandian, Y. Ghasemi, Designing an efficient multi-epitope peptide vaccine against *Vibrio cholerae* via combined immunoinformatics and protein interaction based approaches, *Comput. Biol. Chem.* 62 (2016) 82–95 Jun.
- [141] B. Livingston, et al., A rational strategy to design multi-epitope immunogens based on multiple Th lymphocyte epitopes, *J. Immunol.* 168 (11) (2002) 5499–5506 Jun.
- [142] H. Koprowski, D.B. Weiner (Eds.), *DNA Vaccination/Genetic Vaccination*, Springer-Verlag, Berlin Heidelberg, 1998.
- [143] Y. Kou, et al., Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis, *Immunol. Lett.* 190 (2017) 51–57 Oct.
- [144] S. Kreiter, et al., Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals, *J. Immunol.* 180 (1) (2007) 309–318 Dec.
- [145] S. Arya, Q. Lin, N. Zhou, X. Gao, J.-D. Huang, Strong immune responses induced by direct local injections of modified mRNA-lipid nanocomplexes, *Molecular Therapy - Nucleic Acids* 19 (2020) 1098–1109 Mar.
- [146] D.R. Gallie, The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency, *Genes Dev.* 5 (11) (1991) 2108–2116 Nov.
- [147] D. Munroe, A. Jacobson, mRNA poly(A) tail, a 3' enhancer of translational initiation, *Mol. Cell. Biol.* 10 (7) (1990) 3441–3455 Jul.
- [148] Y. Zhao, et al., Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, *Cancer Res.* 70 (22) (2010) 9053–9061 Oct.
- [149] N. Elango, S. Elango, P. Shivshankar, M.S. Katz, Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector, *Biochem. Biophys. Res. Commun.* 330 (3) (2005) 958–966 May.
- [150] S. Holtkamp, et al., Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells, *Blood* 108 (13) (2006) 4009–4017 Dec.
- [151] I.Y. Tcherepanova, et al., Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion, *BMC Mol. Biol.* 9 (1) (2008) 90.
- [152] M. Mockey, C. Gonçalves, F.P. Dupuy, F.M. Lemoine, C. Pichon, P. Midoux, mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with poly(A) chains in cis and in trans for a high protein expression level, *Biochem. Biophys. Res. Commun.* 340 (4) (2006) 1062–1068 Feb.
- [153] P. Bernstein, S.W. Peltz, J. Ross, The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro, *Mol. Cell. Biol.* 9 (2) (1989) 659–670 Feb.
- [154] Z. Wang, N. Day, P. Trifillis, M. Kiledjian, An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro, *Mol. Cell. Biol.* 19 (7) (1999) 4552–4560 Jul.
- [155] C.N. Magnan, et al., High-throughput prediction of protein antigenicity using protein microarray data, *Bioinformatics* 26 (23) (2010) 2936–2943 Oct.
- [156] M.R. Wilkins, et al., Protein identification and analysis tools in the ExPASy server, *2-D Proteome Analysis Protocols* 2019, pp. 531–552.
- [157] N. Rapin, O. Lund, M. Bernaschi, F. Castiglione, Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system, *PLoS One* 5 (4) (2010), e9862. Apr.
- [158] F. Castiglione, F. Mantile, P. De Berardinis, A. Prisco, How the interval between prime and boost injection affects the immune response in a computational model of the immune system, *Computational and Mathematical Methods in Medicine* 2012 (2012) 1–9.

- [159] J.D. Ooi, et al., Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells, *Nature* 545 (7653) (2017) 243–247 May.
- [160] J.I. Mobbs, et al., The molecular basis for peptide repertoire selection in the human leukocyte antigen (HLA) C*06:02 molecule, *J. Biol. Chem.* 292 (42) (2017) 17203–17215 Aug.
- [161] R.P.D. Bank, RCSB PDB - 4LCY: crystal structure of HLA-b46 at 1.6 angstrom resolution, www.rcsb.org, [Online]. Available <https://www.rcsb.org/structure/4lcy>. (Accessed 15 June 2020).
- [162] J.-P. Routy, et al., Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy, *Clin. Immunol.* 134 (2) (2010) 140–147 Feb.
- [163] R.T. Gandhi, et al., Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef, *JAIDS Journal of Acquired Immune Deficiency Syndromes* 71 (3) (2016) 246–253 Mar.
- [164] J.M. Richner, et al., Modified mRNA vaccines protect against Zika virus infection, *Cell* 168 (6) (2017) 1114–1125.e10 Mar.
- [165] M. Schnee, et al., An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs, *PLoS Negl. Trop. Dis.* 10 (6) (2016), e0004746. Jun.
- [166] M. Alberer, et al., Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial, *Lancet* 390 (10101) (2017) 1511–1520 Sep.
- [167] K. Bahl, et al., Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses, *Mol. Ther.* 25 (6) (2017) 1316–1327 Jun.
- [168] Z. Zhang, et al., Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA, *Immunity* 45 (4) (2016) 737–748 Oct.
- [169] H. Tanji, et al., Toll-like receptor 8 senses degradation products of single-stranded RNA, *Nat. Struct. Mol. Biol.* 22 (2) (2015) 109–115 Jan.
- [170] A. Isaacs, R.A. Cox, Z. Rotem, Foreign nucleic acids as the stimulus to make interferon, *Lancet* 282 (7299) (1963) 113–116 Jul.
- [171] I.J. Amanna, N.E. Carlson, M.K. Slika, Duration of humoral immunity to common viral and vaccine antigens, *N. Engl. J. Med.* 357 (19) (2007) 1903–1915 Nov.
- [172] B.W. Kareko, et al., Persistence of neutralizing antibody responses among yellow fever virus 17D vaccinees living in a nonendemic setting, *J. Infect. Dis.* 221 (12) (Sep. 2019) 2018–2025.
- [173] B. Combadiere, et al., Distinct time effects of vaccination on long-term proliferative and IFN- γ -producing T cell memory to smallpox in humans, *J. Exp. Med.* 199 (11) (2004) 1585–1593 Jun.
- [174] V. Kalia, S. Sarkar, T.S. Gourley, B.T. Rouse, R. Ahmed, Differentiation of memory B and T cells, *Curr. Opin. Immunol.* 18 (3) (2006) 255–264 Jun.
- [175] V. Vetter, G. Denizer, L.R. Friedland, J. Krishnan, M. Shapiro, Understanding modern-day vaccines: what you need to know, *Ann. Med.* 50 (2) (2017) 110–120 Nov.
- [176] T. Hamaoka, J. Shimizu, T. Suda, H. Fujiwara, Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells, *Princess Takamatsu Symp.* 19 (1 Supplement) (May 1988) 265–275.
- [177] J.L. Sanchez-Trincado, M. Gomez-Perosanz, P.A. Reche, Fundamentals and methods for T- and B-cell epitope prediction, *J Immunol Res* 2017 (2017) 1–14.
- [178] S. Rosendahl Huber, J. van Beek, J. de Jonge, W. Luytjes, D. van Baarle, T cell responses to viral infections – opportunities for peptide vaccination, *Front. Immunol.* 5 (Apr. 2014).
- [179] U. Dittmer, K.E. Peterson, R. Messer, I.M. Stromnes, B. Race, K.J. Hasenkrug, Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to friend retrovirus infection, *J. Virol.* 75 (2) (2001) 654–660 Jan.
- [180] D.A. Chesler, C.S. Reiss, The role of IFN- γ in immune responses to viral infections of the central nervous system, *Cytokine Growth Factor Rev.* 13 (6) (2002) 441–454 Dec.
- [181] J.M. Rojas, M. Avia, V. Martín, N. Sevilla, IL-10: a multifunctional cytokine in viral infections, *J Immunol Res* 2017 (2017) 1–14.
- [182] R.V. Luckheeram, R. Zhou, A.D. Verma, B. Xia, CD4+T cells: differentiation and functions, *Clin. Dev. Immunol.* 2012 (2012) 1–12.
- [183] S.M. Kaech, E.J. Wherry, Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection, *Immunity* 27 (3) (2007) 393–405 Sep.
- [184] S.M. Kaech, R. Ahmed, Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells, *Nat. Immunol.* 2 (5) (2001) 415–422 May.
- [185] L. Sabbagh, et al., The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis, *J. Immunol.* 173 (9) (2004) 5425–5433 Oct.
- [186] F.D. Batista, D. Iber, M.S. Neuberger, B cells acquire antigen from target cells after synapse formation, *Nature* 411 (6836) (2001) 489–494 May.
- [187] P.D. Hodgkin, B.E. Castle, M.R. Kehry, B cell differentiation induced by helper T cell membranes: evidence for sequential isotype switching and a requirement for lymphokines during proliferation, *Eur. J. Immunol.* 24 (1) (1994) 239–246 Jan.
- [188] N.J. Kräutler, et al., Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells, *J. Exp. Med.* 214 (5) (2017) 1259–1267 Mar.
- [189] A. Mitchison, Latent help to and from H-2 antigens, *Eur. J. Immunol.* 22 (1) (1992) 123–127 Jan.
- [190] D.N. Forthal, Functions of antibodies, *Microbiology Spectrum* 2 (4) (2014) Aug.
- [191] B.P. O'Connor, M. Cascalho, R.J. Noelle, Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population, *J. Exp. Med.* 195 (6) (2002) 737–745 Mar.
- [192] S. Duffy, Why are RNA virus mutation rates so damn high? *PLoS Biol.* 16 (8) (2018), e3000003. Aug.
- [193] I. Ahammad, M.R.I. Sarker, A.M. Khan, S. Islam, M. Hossain, Virtual screening to identify novel inhibitors of Pan ERBB family of proteins from natural products with known anti-tumorigenic properties, *Int. J. Pept. Res. Ther.* (2019) <https://doi.org/10.1007/s10989-019-09992-3> Dec, [Online].
- [194] T.K. George, A. Tomy, M.S. Jisha, Molecular docking study of bioactive compounds of *Withania somnifera* extract against topoisomerase IV type B, *Proceedings of the National Academy of Sciences, India Section B: Biological Sciences* 90 (2) (2019) 381–390 Jun.
- [195] S. Yadav, S.K. Pandey, V.K. Singh, Y. Goel, A. Kumar, S.M. Singh, Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: implication in designing of novel anticancer therapeutic strategies, *PLoS One* 12 (5) (2017), e0176403. May.
- [196] M. Aamir, et al., In silico prediction, characterization, molecular docking, and dynamic studies on fungal SDRs as novel targets for searching potential fungicides against *Fusarium wilt* in tomato, *Front. Pharmacol.* 9 (2018) Oct.
- [197] M. Tahir ul Qamar, S. Saleem, U.A. Ashfaq, A. Bari, F. Anwar, S. Alqahtani, Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study, *J. Transl. Med.* 17 (1) (2019) Nov.
- [198] M.A. Khan, M.U. Hossain, S.M. Rakib-Uz-Zaman, M.N. Morshed, Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study, *Scand. J. Immunol.* 82 (1) (2015) 25–34 Jun.
- [199] R.A. Tahir, H. Wu, M.A. Rizwan, T.H. Jafar, S. Saleem, S.A. Sehgal, Immunoinformatics and molecular docking studies reveal potential epitope-based peptide vaccine against DENV-NS3 protein, *J. Theor. Biol.* 459 (2018) 162–170 Dec.
- [200] Y. Fu, J. Zhao, Z. Chen, Insights into the molecular mechanisms of protein-ligand interactions by molecular docking and molecular dynamics simulation: a case of oligopeptide binding protein, *Computational and Mathematical Methods in Medicine* 2018 (Dec. 2018) 1–12.
- [201] I.V. Oferkin, et al., Evaluation of docking target functions by the comprehensive investigation of protein-ligand energy minima, *Adv. Bioinforma.* 2015 (2015) 1–12.
- [202] B.K. Ho, A. Thomas, R. Brasseur, Revisiting the Ramachandran plot: hard-sphere repulsion, electrostatics, and H-bonding in the α -helix, *Protein Sci.* 12 (11) (2009) 2508–2522 Jan.
- [203] S.A. Hollingsworth, P.A. Karplus, A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins, *BioMolecular Concepts* 1 (3–4) (2010) Jan.
- [204] M. Wiederstein, M.J. Sippl, ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins, *Nucleic Acids Res.* 35 (Web Server) (2007) W407–W410 May.
- [205] P.A. Kriegel, D.A. Melton, [25] In vitro RNA synthesis with SP6 RNA polymerase, *Methods Enzymol.* (1987) 397–415.
- [206] J.F. Milligan, D.R. Groebe, G.W. Witherell, O.C. Uhlenbeck, Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates, *Nucleic Acids Res.* 15 (21) (1987) 8783–8798.
- [207] E.T. Schenborn, R.C. Mierendorf, A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure, *Nucleic Acids Res.* 13 (17) (1985) 6223–6236.
- [208] K. Karikó, H. Muramatsu, J. Ludwig, D. Weissman, Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA, *Nucleic Acids Res.* 39 (21) (2011) e142 Sep.
- [209] C. De Haro, R. Méndez, J. Santoyo, The eIF-2 α kinases and the control of protein synthesis 1, *FASEB J.* 10 (12) (1996) 1378–1387 Oct.
- [210] S.-L. Liang, D. Quirk, A. Zhou, RNase L: its biological roles and regulation, *IUBMB Life (International Union of Biochemistry and Molecular Biology: Life)* 58 (9) (2006) 508–514 Sep.
- [211] A. Isaacs, R.A. Cox, Z. Rotem, Foreign nucleic acids as the stimulus to make interferon, *Lancet* 282 (7299) (1963) 113–116 Jul.
- [212] A.K. Field, A.A. Tytell, G.P. Lampson, M.R. Hilleman, Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes, *Proc. Natl. Acad. Sci.* 58 (3) (1967) 1004–1010 Sep.
- [213] M. Absher, W.R. Stinebring, Toxic properties of a synthetic double-stranded RNA: endotoxin-like properties of poly I. Poly C, an interferon stimulator, *Nature* 223 (5207) (1969) 715–717 Aug.
- [214] B. Scheel, et al., Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA, *Eur. J. Immunol.* 35 (5) (2005) 1557–1566 May.
- [215] Z. Xiang, H.C.J. Ertl, Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines, *Immunity* 2 (2) (1995) 129–135 Feb.
- [216] A. Iwasaki, B.J. Stiernholm, A.K. Chan, N.L. Berinstein, B.H. Barber, Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines, *J. Immunol.* 158 (10) (1997) 4591–4601 May.
- [217] M. Geissler, A. Gesien, K. Tokushige, J.R. Wands, Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids, *J. Immunol.* 158 (3) (Feb. 1997) 1231–1237.

- [218] P.T. Loudon, et al., GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human Primates, *PLoS One* 5 (6) (2010), e11021. Jun.
- [219] S. Venkatesan, A. Gershowitz, B. Moss, Modification of the 5' end of mRNA. Association of RNA triphosphatase with the RNA guanylyltransferase-RNA (guanine-7-) methyltransferase complex from vaccinia virus, *J. Biol. Chem.* 255 (3) (Feb. 1980) 903–908.
- [220] S.A. Martin, E. Paoletti, B. Moss, Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions, *J. Biol. Chem.* 250 (24) (Dec. 1975) 9322–9329.
- [221] J. Stepinski, C. Waddell, R. Stolarski, E. Darzynkiewicz, R.E. Rhoads, Synthesis and properties of mRNAs containing the novel 'anti-reverse' cap analogs 7-methyl (3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG, *RNA (New York, N.Y.)* 7 (10) (Oct. 2001) 1486–1495.
- [222] E. Grudzien, M. Kalek, J. Jemielity, E. Darzynkiewicz, R.E. Rhoads, Differential inhibition of mRNA degradation pathways by novel cap analogs, *J. Biol. Chem.* 281 (4) (2005) 1857–1867 Oct.
- [223] F.T. Zohra, E.H. Chowdhury, S. Tada, T. Hoshiba, T. Akaike, Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection, *Biochem. Biophys. Res. Commun.* 358 (1) (2007) 373–378 Jun.
- [224] E. Grudzien-Nogalska, J. Jemielity, J. Kowalska, E. Darzynkiewicz, R.E. Rhoads, Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells, *RNA* 13 (10) (2007) 1745–1755 Aug.
- [225] M. Kozak, Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs, *Mol. Cell. Biol.* 9 (11) (1989) 5134–5142 Nov.
- [226] M. Kozak, A short leader sequence impairs the fidelity of initiation by eukaryotic ribosomes, *Gene Expr.* 1 (2) (May 1991) 111–115.
- [227] G.S. Wilkie, K.S. Dickson, N.K. Gray, Regulation of mRNA translation by 5'- and 3'-UTR-binding factors, *Trends Biochem. Sci.* 28 (4) (2003) 182–188 Apr.
- [228] R.W. Malone, P.L. Felgner, I.M. Verma, Cationic liposome-mediated RNA transfection, *Proc. Natl. Acad. Sci. U. S. A.* 86 (16) (1989) 6077–6081 Aug.
- [229] J.-P. Carralot, et al., Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas, *Genetic Vaccines and Therapy* 3 (1) (2005) 6.
- [230] G. Kudla, L. Lipinski, F. Caffin, A. Helwak, M. Zyllicz, High guanine and cytosine content increases mRNA levels in mammalian cells, *PLoS Biol.* 4 (6) (2006) e180 May.
- [231] A. Thess, et al., Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals, *Mol. Ther.* 23 (9) (2015) 1456–1464 Sep.
- [232] C. Gustafsson, S. Govindarajan, J. Minshull, Codon bias and heterologous protein expression, *Trends Biotechnol.* 22 (7) (2004) 346–353 Jul.
- [233] F. Buhr, et al., Synonymous codons direct cotranslational folding toward different protein conformations, *Mol. Cell* 61 (3) (2016) 341–351 Feb.
- [234] C.-H. Yu, et al., Codon usage influences the local rate of translation elongation to regulate co-translational protein folding, *Mol. Cell* 59 (5) (2015) 744–754 Sep.
- [235] S. Kanaya, Y. Yamada, M. Kinouchi, Y. Kudo, T. Ikemura, Codon usage and tRNA genes in eukaryotes: correlation of codon usage diversity with translation efficiency and with CG-dinucleotide usage as assessed by multivariate analysis, *J. Mol. Evol.* 53 (4–5) (2001) 290–298 Oct.
- [236] L. Duret, Evolution of synonymous codon usage in metazoans, *Curr. Opin. Genet. Dev.* 12 (6) (2002) 640–649 Dec.
- [237] K. Karikó, et al., Incorporation of Pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability, *Mol. Ther.* 16 (11) (2008) 1833–1840 Nov.
- [238] O. Andries, S. Mc Cafferty, S.C. De Smedt, R. Weiss, N.N. Sanders, T. Kitada, N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice, *Journal of Controlled Release: Official Journal of the Controlled Release Society* 217 (Nov. 2015) 337–344.
- [239] B.R. Anderson, et al., Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation, *Nucleic Acids Res.* 38 (17) (2010) 5884–5892 Sep.
- [240] B.R. Anderson, H. Muramatsu, B.K. Jha, R.H. Silverman, D. Weissman, K. Kariko, Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L, *Nucleic Acids Res.* 39 (21) (2011) 9329–9338 Aug.
- [241] K. Karikó, M. Buckstein, H. Ni, D. Weissman, Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA, *Immunity* 23 (2) (2005) 165–175 Aug.
- [242] N. Pardi, et al., Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes, *J. Control. Release* 217 (2015) 345–351 Nov.
- [243] H.H. Tam, et al., Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination, *Proc. Natl. Acad. Sci.* 113 (43) (2016) E6639–E6648 Oct.
- [244] K. Bahl, et al., Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses, *Mol. Ther.* 25 (6) (2017) 1316–1327 Jun.
- [245] D. Fang, et al., Transient T-bet expression functionally specifies a distinct T follicular helper subset, *J. Exp. Med.* 215 (11) (2018) 2705–2714 Sep.
- [246] C. Snapper, W. Paul, Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production, *Science* 236 (4804) (1987) 944–947 May.